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Abstract: Impulse control disorders (ICDs) occur in a subset of Parkinson’s disease (PD) patients on dopaminergic 
medications however there are currently no reliable markers to identify patients at risk. Sleep disturbances are more common 
in patients with an ICD. Serum ferritin levels have been associated with PD disease stage and progression, but have not 
previously been associated with impulsivity levels. The objective of this study was to determine if serum ferritin levels and 
sleep disturbance are associated with high traits of impulsivity and ICD in a cohort of PD patients attending a movement 
disorders clinic. This study assessed impulsiveness in 87 PD patients using the Barratt Impulsiveness Scale. Severity of sleep 
disturbance was determined using the sleep-related items of the MDS-UPDRS. Serum ferritin, iron and transferrin levels were 
measured in patients, as well as 36 age-matched healthy controls. Serum ferritin levels were significantly elevated in male PD 
patients in the high impulsivity group compared to patients in the low (p=.022) and normal range groups (p=.024) and showed 
a linear increase across the three groups. Sleep disturbance also demonstrated a linear trend, which was most severe in the high 
impulsivity group (p=.030). A subgroup of 11 male PD patients who fulfilled the DSM-5 criteria for an ICD had significantly 
higher ferritin levels and more severe sleep disturbance when compared with the remaining male PD cohort. Serum ferritin 
levels and sleep disturbance severity are highlighted as potential markers for abnormal impulsivity and ICD in PD patients. 
Keywords: Impulsivity, BIS-11, Ferritin, Sleep Disturbance, PD 
 
1. Introduction 
Impulse control disorders (ICDs) are becoming 
increasingly identified as a consequence of dopaminergic 
medication in Parkinson’s disease (PD) [1]. Recent studies 
suggest ICDs occur in upwards of 40% of PD patients [2], 
with males more likely to report multiple impulsive 
behaviours than females [3]. While there are currently no 
reliable predictive markers for the development of an ICD, 
patients with higher traits of impulsivity may be more 
susceptible, although this is yet to be established. Patients 
displaying high impulsivity traits are known to have a 
younger age at PD onset [3] and are also more likely to be 
individuals who have recurrent falls [4]. 
Sleep deprivation and disturbances are known to increase 
impulsive behaviours [5]. Moreover, patients with PD 
experience greater sleep-related problems [6], a feature 
possibly exacerbated by medications such as dopamine 
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agonists [7, 8]. Sleep disturbances, including sleep 
fragmentation and daytime sleepiness, are more common in 
PD patients with ICDs than PD alone and healthy controls 
[9]. Similar patterns of sleep disturbance have been linked to 
impulsive behaviour in other related disorders such as 
Attention Deficit/Hyperactivity Disorder (ADHD) and 
restless legs syndrome (RLS) [10, 11], both of which have 
been associated with low serum levels of the iron storage 
protein, ferritin [12, 13]. Moreover, in a study of children 
with ADHD, Oner and colleagues (2012) identified a 
relationship between serum ferritin and hyperactivity scores 
[14], presenting a possible marker for broader impulse 
control conditions. 
A number of studies have shown that there is a selective 
accumulation of iron in the substantia nigra in PD [15] and 
changes in levels of the major iron-binding protein ferritin, 
however it is unclear what role they play in the pathogenesis 
of the disease [16]. Studies examining serum levels of ferritin 
in PD patients have been inconclusive, showing either 
increased levels [17], or no significant relationship [18, 19]. 
Ferritin levels have been reported to be increased in both 
male and female PD patients when compared to controls, 
correlating with Hoehn & Yahr stage and disease duration 
[20]. However, limited studies have investigated ferritin 
levels during disease progression, most importantly in the 
context of non-motor aspects of the disease, and an 
association between ferritin and impulsivity levels has not 
previously been investigated. 
Thus, the present study investigated whether trait 
impulsivity was associated with sleep disturbance and serum 
levels of ferritin, iron and transferrin in a cohort of PD 
patients without a prior history of an ICD. 
2. Methods 
2.1. Subjects 
Eighty-seven home-based PD patients (54 males) were 
sequentially recruited from the Movement Disorders Clinic at 
the Perron Institute for Neurological and Translational 
Science (Perth, Australia) between 2008 and 2015. All 
patients were examined by a movement disorder neurologist 
prior to inclusion in the study for verification of the diagnosis 
in accordance with the UK Brain Bank criteria for IPD [21]. 
All PD patients were taking levodopa and 49 patients were 
also on a dopamine agonist (cabergoline, pramipexole, 
ropinirole or rotigotine). All PD medications were converted 
to levodopa equivalent daily doses (LEDD) [22]. Fourteen 
patients had implanted GPi deep brain stimulators (DBS). 
None of the patients had a history of liver disease or of a 
chronic inflammatory or iron storage disorder. For serum 
analysis, 36 age-matched healthy control samples were also 
collected. This study was approved by the Sir Charles 
Gairdner Hospital Human Research and Ethics Committee 
(Approval number 2006/073), and written informed consent 
was obtained from all participants, in accordance with the 
National Health and Medical Research Council guidelines. 
2.2. Clinical Assessments and Diagnosis of Impulse Control 
Disorders 
All clinical assessments were evaluated in the ‘ON’ state. 
Motor symptoms were evaluated using the MDS-Unified 
Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, 
and Hoehn and Yahr Scale [23]. In addition, each participant 
was evaluated by a clinical psychologist and completed a 
battery of neuropsychological assessments. The ‘Barratt 
Impulsivity Scale 11’ (BIS-11) was employed as a validated 
self-report questionnaire for screening impulsivity [24]. 
During the screening process, patients displaying any signs 
of an impulse control disorder were invited to seek further 
consultation with the clinical psychologist. Patients attending 
the subsequent consultation underwent a formal 
psychological evaluation, whereby a formal diagnosis of ICD 
was made based on the DSM-5 diagnostic criteria [25]. 
Venous blood samples were collected from patients and 
controls at the time of clinical assessment. For serum analysis 
of ferritin, transferrin, and iron, blood was collected from all 
PD patients and healthy controls. 
2.3. Determination of Sleep Problems 
Patient sleep disturbance was calculated by combining 
patient ‘night-time sleep problems’ (MDS-UPDRS item 1.7) 
and ‘daytime sleepiness’ (MDS-UPDRS 1.8). This combined 
score has previously been validated against other scales for 
measuring sleep disturbances, such as the ‘Epworth 
Sleepiness Scale’ and the ‘PD Sleep Scale Version 2’ (PDSS-
2) [26]. 
2.4. Statistical Methods 
Data was analysed using IBM-SPSS (v. 24, IBM 
Corporation). A significant nominal P-value of ≤0.05 was 
employed. One-way analysis of variance (ANOVA) tests 
with Tukey post-hoc analysis were used to compare the 
difference between defined impulsivity groups. In addition, 
the assessment for homogeneity of variance between groups 
was undertaken using Levene’s test. In addition to the 
ANOVA, for the assessment of covariates such as age, an 
analysis of covariance (ANCOVA) was undertaken, and 
described where appropriate. For gender comparisons, and 
comparison between demographic variables, independent t-
tests or Mann-Whitney U were used. 
3. Results 
3.1. Demographic and Clinical Correlates of Impulsivity in 
PD Patients 
The PD cohort enrolled in this study has previously been 
described [27], and was broadly ranging in age (68.9 ± 31.8 
yrs), age of onset (53.3 ± 10.2 yrs), and disease duration 
(10.4 ± 6.8 yrs) and had no prior history of an ICD. In an 
effort to identify demographic and clinical indicators of 
patient impulsivity, the effects of gender, smoking history, 
PD medications and DBS surgery were examined and no 
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significant associations were found with the total BIS-11 
impulsivity scores (data not shown). 
To determine if patient impulsivity was associated with 
other clinical markers in PD, BIS-11 scores were grouped 
into low (<52), normal (52-71) and high levels (>72) [24]. 
Given the previously reported link between recurrent falling 
and patient impulsivity in PD, this study first examined 
gender differences in disease severity, as determined by 
motor examination (MDS-UPDRS III). Patients self-
reporting higher traits of impulsivity displayed a worsened 
disease severity, with significance only between groups in 
male PD patients (p<.05). Given the established link between 
impulsivity and sleep disturbance, the authors subsequently 
investigated whether patients in this cohort exhibited a 
similar relationship. Sleep disturbance in patients, as 
measured by UPDRS 1.7 and 1.8, was significantly 
associated with impulsivity groups (p<.05). Sleep 
disturbance scores were significantly higher in the high 
impulsivity group (p<.026), compared to patients in the 
normal-range group. Moreover, this association was observed 
in male, but not female patients (Figure 1B). 
Table 1. Descriptive statistics of the Parkinson’s Disease cohort (n=87). 
Clinical Characteristic/Assessment Mean (±SD) 
Age (Years) 68.9 (31.8) 
Age of onset (Years) 53.3 (10.2) 
BIS-11 61.8 (10.0) 
Disease duration (Years) 10.4 (6.8) 
Daily LD equivalents (mg/day) 671 (389) 
Hoehn Yahr (Stage 0-4) 1.6 (1.0) 
MDS-UPDRS III Score 12.8 (14.2) 
LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale 
3.2. Impulsivity Levels Relate to Serum Ferritin and 
Transferrin Saturation Levels 
Serum ferritin levels were elevated in the overall cohort of 
PD patients (n=87) when compared to healthy age-matched 
controls (n=36), however this difference did not reach 
statistical significant. When the effect of gender was 
considered, elevated ferritin levels were observed in male PD 
patients and healthy controls, when compared to females 
(p<.001), but there were no significant differences between 
PD patients and controls (Figure 2A). Serum ferritin levels 
showed a significant main effect between impulsivity groups 
(p<.05), with a significant increase in the high impulsivity 
group when compared to the normal and low impulsivity 
groups (p<.05). Male patients displayed a greater difference 
in serum ferritin between impulsivity groups (p<.05), with an 
incremental rise in the three groups (Figure 2B). In contrast, 
female PD patients did not demonstrate the same significant 
relationship between impulsivity groups. 
In the whole cohort of PD patients, serum iron and 
transferrin saturation were not significantly altered, when 
compared to healthy age-matched controls (Figure 2C and 
2E). When analysing the effect of gender, elevated iron levels 
were observed in male patients within the high impulsivity 
group (Figure 2D), but these results did not reach 
significance (p=.054). Transferrin saturation (serum iron 
level x 100 / total iron-binding capacity) showed no 
difference in the low and normal range impulsivity groups. 
However, male patients in the high impulsivity group 
displayed significantly higher transferrin saturation levels 
than female patients (p<.05) in the same group (Figure 2F). 
To confirm these findings, ANCOVA analysis using age 
and LEDD as covariates were performed. In the male cohort, 
age and LEDD were not significant contributors to the 
observed variance in ferritin levels. Moreover, impulsivity 
(BIS-11) grouping was a significant variable (p<.05), and 
pairwise comparisons of adjusted means revealed 
significance between high and normal impulsivity groups 
(p=.010). 
		
Figure 1. Clinical assessment indicators of impulsivity scores (BIS-11). When PD patients were grouped by impulsivity scores: (A) patients in the high 
impulsivity group had greater disease severity (MDS-UPDRS III), reaching statistical significance in male groups. (B) Gender-specific differences in sleep 
disturbance between impulsivity groups with an incremental increase in severity of sleep disturbance in males. Data shown are the mean ± standard error; 
*p<.05: **p<.005. 
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Figure 2. Serum ferritin, iron and transferrin saturation levels. (A) Ferritin levels were significantly higher in males than females both in the PD and control 
groups (B) Gender-specific differences in serum ferritin levels between impulsivity groups with an incremental rise in male PD patients but not females. (C) 
Serum iron levels were not significantly altered between control subjects compared with PD patients, or (D) between impulsivity groups. (E) Transferrin 
saturation percentage was not significantly altered between control subjects compared with PD patients. (F) Within the high range impulsivity group, 
transferrin saturation percentage was elevated in males but not females. Data shown are the mean ± standard error; *p<.05, **p<.005, ***p<.001. 
3.3. Subset of Patients Diagnosed with an ICD 
Following the preliminary psychological assessment and administration of the BIS-11, 11 patients (all males) with the 
highest impulsivity scores volunteered to undergo a more detailed evaluation by a clinical psychologist and were all found to 
meet the DSM-5 criteria for the diagnosis of an ICD. Their demographic and clinical features are detailed in Table 2 in 
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Table 2. Baseline Clinical Characteristics of the male PD (n=43), and diagnosed ICD patient subset (n=11). 
Clinical Characteristic/Assessment Male PD patients Mean (± SD) ICD subset Mean (± SD) 
Age (Years) 62.95 (11.1) 63.55 (7.4) 
Age of onset (Years) 52.98 (12.0) 52.64 (8.3) 
Disease duration (Years) 11.05 (7.6) 11.73 (6.2) 
Daily LD equivalents (mg/day) 755.5 (424.6) 590.9 (375.3) 
Hoehn Yahr (Stage 0-4) 1.67 (0.9) 1.73 (1.1) 
UPDRS III Score 18.30 (13.81) 24.09 (14.73) 
LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale 
 
Figure 3. Comparative assessments of serum markers in ICD, male PD and male healthy controls. (A) Ferritin levels were significantly higher in ICD males 
compared to PD males, but not healthy controls (B) Serum iron levels were not significantly different between groups. (C) Transferrin levels were significantly 
reduced in the ICD group when compared with healthy control males. (D) Transferrin saturation was significantly elevated in the ICD cohort, when compared 
to males in the control and PD groups. (E) Patient sleep disturbance was significantly greater in males with an ICD compared with the male PD patients. 
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3.4. Male ICD Patients show Higher Serum Ferritin Levels 
and Greater Sleep Disturbance 
To determine if findings relating to serum ferritin, iron, 
and transferrin saturation were also observed between 
groups, serum levels were compared between the subset of 
ICD patients, other male PD patients, and healthy male 
controls (Figure 3). Significantly higher ferritin levels and 
transferrin saturation, and significantly lower transferrin 
levels were observed in the ICD group when compared to the 
other male PD patients and healthy control males (p<.05). 
Serum iron levels were significantly higher than in the other 
PD males, but not male healthy controls. Similarly, self-
reported sleep disturbance (UPDRS 1.7 and 1.8) was greater 
in the ICD subset, when compared to the other PD male 
group (p=.038). 
4. Discussion 
Findings from the present study demonstrated that when 
impulsivity scores were stratified into low, normal and high 
levels, male patients in the high impulsivity group had 
significantly greater motor impairment, as shown by higher 
UPDRS III scores, than males in the normal or low 
impulsivity groups. Interestingly, despite a similar trend with 
female patients, no significant differences in UPDRS III 
scores were observed between impulsivity groups. Similarly, 
the authors also observed a gender specific difference in the 
severity of sleep disturbance, with males in the high 
impulsivity group reporting greater disturbances then 
females. In addition, an incremental increase in sleep 
disturbance severity was observed in males across the three 
impulsivity groups. The basis for the association between 
sleep disturbance and impulsiveness is uncertain, specifically 
whether sleep disturbance increases impulsivity and the risk 
of developing an ICD, or is a consequence of it [1]. Rapid 
eye movement sleep associated behavioral disorder (RBD), 
which is common in PD patients, has also been associated 
with male gender, as well as longer disease duration, and 
medication doses [28]. While ICDs have recently been linked 
to RBD [29], polysomnography studies have failed to 
confirm an association between the two disorders, suggesting 
that they do not have a common underlying pathophysiology 
[30]. 
While the literature is divided on whether serum ferritin 
levels are elevated in PD, results from the present cohort 
indicated overall levels were higher in PD patients than 
controls, but these results did not reach statistical 
significance (p=.056), while serum iron and transferrin 
saturation levels were comparable in the two groups. After 
stratifying for gender serum ferritin levels were found to be 
higher in males, both in the PD and control groups, as 
previously reported [31-33]. 
There are few studies linking ferritin and impulsivity, and 
the present study is the first to demonstrate an association 
between ferritin levels and high impulsivity in PD patients. 
This was found to be gender-specific, in that it was present 
only in males, and there was a progressive increase in ferritin 
levels across the three impulsivity groups. Males in the high 
impulsivity group, who also had the greatest degree of sleep 
disturbance, had the highest ferritin levels (p<.05) as well as 
increased transferrin saturation (p<.05) and raised serum iron 
levels (p=.054), in keeping with a state of relative iron over-
load. 
On the basis of the initial BIS-11 screening assessment we 
identified a subset of male patients with high impulsivity 
scores who fulfilled the diagnostic criteria for an ICD. This 
subset consisted of 11 male patients who were diagnosed by 
a clinical psychologist and appeared to present with a 
somewhat greater disease severity (UPDRS III score), when 
compared to the remaining male PD patient cohort. Unlike 
previous studies, the ICD subset were not of early disease 
onset or longer disease duration [3], with findings showing 
age, disease duration and age of disease not being significant 
variables of ICD prevalence in PD. Despite being of similar 
age and disease duration, the ICD subset also displayed 
significantly greater ferritin levels and transferrin saturation 
when compared to the other male PD patients (p<.05), and 
elevated transferrin saturation compared to healthy controls. 
Moreover, consistent with the high impulsivity group, as 
determined by BIS-11 scores, the ICD subset reported 
significantly greater sleep disturbance than male PD patients 
(p<.05). These results are somewhat surprising, as low brain 
iron levels have been associated with increased sleep 
disturbances and sleep fragmentation [34], a feature 
documented in RLS [35]. However, it is known that patients 
suffering from iron overload syndromes can also experience 
similar sleep-related difficulties [36]. 
5. Limitations 
Patient medication was optimised, and patient selection 
was made on the basis of independence and mobility in that 
those unable to walk unassisted were excluded, as 
demonstrated by a comparatively low mean cohort Hoehn 
and Yahr score. A number of limitations need to be 
acknowledged. Firstly, while validated against standard 
measures of sleep quality [26], interpretations of sleep 
disturbance using self-reported questions from the MDS-
UPDRS should be considered with caution. Secondly, 
following initial evaluation, not all patients with high 
impulsivity scores volunteered to undergo a more detailed 
follow-up consultation with a clinical psychologist and the 
incidence of ICD may have been underestimated. As such, a 
‘non-ICD’ patient subset could not be accurately determined, 
and the manuscript acknowledges this limitation by 
comparing the ICD group with the other male patients in the 
cohort. Thirdly, although none of the PD patient cohort were 
known to have any other condition that might be associated 
with an elevated serum ferritin level, laboratory 
investigations to exclude secondary causes of raised ferritin 
levels were not carried out. Lastly, in view of the multiple 
51 Ryan Scott Anderton et al.:  Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and  
Impulse Control Disorders in Male Parkinson’s Disease Patients 
factors which could contribute to a high impulsivity score in 
a chronic disease such as PD, including premorbid 
personality traits and subsequent effects of the disease itself 
and medications, and in view of the cross-sectional nature of 
this study, caution needs to be exercised in equating high 
impulsivity levels as demonstrated by the BIS-11 screening 
tool with the development of an ICD. Nevertheless, it is 
noteworthy that all of the male patients with the highest 
impulsivity scores were in fact found to fulfill the criteria for 
an ICD on further evaluation. 
6. Conclusions 
In conclusion, using the BIS-11 screening tool, this study 
demonstrated that male PD patients with the highest 
impulsivity levels had significantly higher serum ferritin 
levels and transferrin saturation, and also experienced the 
most severe sleep disturbance. These associations were also 
present in a subset of males who met the DSM-5 criteria for 
an ICD. Although the findings do not necessarily imply a 
causal relationship between high ferritin levels and high 
levels of impulsivity and ICDs they suggest that there may be 
a link between altered iron homeostasis and the development 
of these disorders in males with PD, which warrants further 
investigation. These findings also indicate the value of the 
BIS-11 scale as a screening tool to identify patients who may 
have an ICD who require further evaluation and treatment. 
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